Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) Fails to deliver data
Key failure to deliver metrics for Adaptimmune Therapeutics:
- Last SEC data release: 2024-04-12
- Last 15 days FTD volume: $0.02 M
- Last 3 months FTD volume: $0.27 M
- Last year FTD volume: $3.18 M
Failures to deliver for Adaptimmune Therapeutics (ADAP) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Adaptimmune Therapeutics (ADAP) - since 2015
Volume in USD (price x number of shares), data since 2015Adaptimmune Therapeutics (ADAP) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $0.27 M | -93.67% |
| 2023 | $4.31 M | 424.88% |
| 2022 | $0.82 M | -74.5% |
| 2021 | $3.22 M | -92.83% |
| 2020 | $44.92 M | 883.34% |
| 2019 | $4.56 M | -18.66% |
| 2018 | $5.61 M | 202.64% |
| 2017 | $1.85 M | 182.01% |
| 2016 | $0.65 M | -91.71% |
| 2015 | $7.93 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 uniQure QURE | $0.9 M | $3.62 M | 🇳🇱 Netherlands |
 Novavax NVAX | $37.88 M | $0.32 B | 🇺🇸 USA |
 Exelixis EXEL | $0.82 M | $5.93 M | 🇺🇸 USA |
 Enzo Biochem ENZ | $0 M | $0.63 M | 🇺🇸 USA |